Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Breast Cancer Clinical Trial

Official title:

A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03422679
• Other study ID #: CB103-C-101
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: December 5, 2017
• Est. completion date: November 11, 2022

Study information

• Verified date: January 2024
• Source: Cellestia Biotech AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

Description:

This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages: dose escalation in Part A of the study (Phase I) followed by dose expansion in Part B (Phase IIA). Escalation cohorts will receive repeat doses of CB-103 to determine the MTD and RP2D. CB-103 will be administered orally in treatment cycles of 28-days each. Aim of the expansion Phase IIA, Part B of the study will be to collect preliminary evidence of anti-tumour activity.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 79
• Est. completion date: November 11, 2022
• Est. primary completion date: November 11, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA:

1. Disease

• Patients with histologically or cytologically confirmed solid tumours (breast cancer (triple negative breast cancer [TNBC], ER+/-, HER2+/-), gastrointestinal (GI) cancers (resistant to oxaliplatin or irinotecan-based therapy colorectal cancer [CRC]), osteosarcoma, adenoid cystic carcinoma (ACC), and malignant glomus tumour) that are surgically unresectable, locally advanced, or metastatic and whose disease has progressed on at least one line of systemic therapy (with the exception of ACC patients who are allowed to be systemic treatment-naïve) and for whom no established therapeutic alternatives exist. Any other solid cancer (including lymphoma) with a confirmed NOTCH1-4 activating mutation or genetic lesion.
• Relapsed or refractory (r/r) T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoma (T-LBL) with a confirmed NOTCH pathway activation. Refractory patients are defined as T-ALL/T-LBL patients with = 5% bone marrow blasts, and/or concomitant extramedullary involvement, who have not achieved a CR after standard induction/consolidation therapy attempt.

2. Demography: men and women = 18 years old

3. Adequate organ function and laboratory results

4. Adequate contraceptive measures

5. Signed informed consent EXCLUSION CRITERIA

1. Medical History

1. Patients with symptomatic CNS metastases (neurologically unstable or requiring increasing doses of steroids to control their CNS disease)

2. Hypersensitivity to any of the excipients of CB-103

3. Patients with unresolved nausea, vomiting, or diarrhoea of CTCAE grade > 1

4. Impairment of GI function or presence of GI disease that may significantly alter the absorption of CB-103

5. History of second or other primary cancer with the exception of:

• Curatively treated non-melanomatous skin cancer
• Curatively treated cervical cancer or breast carcinoma in situ
• Other primary solid tumour treated with curative intent and no known active disease present and no treatment administered during the last 2 years.

2. Exclusionary concurrent medical conditions Impaired cardiac function or clinically significant cardiac diseases.

3. Prior Therapy

• In patients with solid tumours cytotoxic chemotherapy within 3 weeks
• In T-ALL/T-LBL patients, prior anticancer therapy less than 2 weeks prior to starting therapy or 5 half-lives (whichever is longer) with exceptions.
• Radiation therapy within 2 weeks of scheduled CB-103 dosing day 1
• Immunotherapy, biological therapies, targeted small molecules, hormonal therapies within 3 weeks of scheduled CB-103 dosing day 1
• Unresolved toxicity CTCAE grade > 1 from previous anti-cancer therapy or radiotherapy (excluding neurotoxicity, alopecia, ototoxicity, lymphopenia), or incomplete recovery from previous surgery.

Related Conditions & MeSH terms

• Adenoid Cystic Carcinoma
• Breast Cancer
• Carcinoma
• Carcinoma, Adenoid Cystic
• Colorectal Cancer
• Glomus Tumor, Malignant
• Hematologic Neoplasms
• Hepatocellular Carcinoma
• Neoplasms
• Non-hodgkin Lymphoma
• Osteosarcoma
• T-ALL

Intervention

Drug:
• CB-103
Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.

Locations

Country	Name	City	State
France	Centre Hospitalier Lyon-Sud	Lyon
France	Hôpital Saint-Louis	Paris
Germany	Charite- Universitaetsmedizin Berlin- Campus Benjamin Franklin	Berlin
Germany	Universitätsklinikum Frankfurt	Frankfurt
Germany	Nationales Centrum für Tumorerkrankungen Heidelberg	Heidelberg
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Severance Hospital - Yonsei Cancer Center	Seoul
Spain	Catalan Institute of Oncology	Barcelona
Spain	Hospital Quirón Barcelona	Barcelona
Spain	Vall d'Hebron Institute of Oncology (VHIO)	Barcelona
Spain	Hospital Ramón y Cajal	Madrid
Switzerland	Oncology Institute of Southern Switzerland	Bellinzona
Switzerland	Kantonsspital St.Gallen	Saint Gallen
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	MD Anderson	Houston	Texas
United States	Sarcoma Oncology Research Center	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Cellestia Biotech AG

Countries where clinical trial is conducted

United States,  France,  Germany,  Korea, Republic of,  Spain,  Switzerland, 

References & Publications (1)

Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schonborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Res Commun. 2023 Sep 14;3(9):1853-1861. doi: 10.1158/2767-9764.CRC-23-0333. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Limiting Toxicity (DLT)	Number of patients with dose limiting toxicity during the first cycle.; DLT is defined as a severe adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications, that occurs = 28 days following the first dose of CB-103 (Cycle 1).	28 days
Secondary	Overall Response Rate	Number of patients with an overall response rate (CR+PR assessed by RECSIT v1.1 or CR or CRi by NCCN guidelines) up to 24 months	24 months